Summit Therapeutics (SMMT) Current Assets (2016 - 2025)
Historic Current Assets for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $246.5 million.
- Summit Therapeutics' Current Assets fell 4973.06% to $246.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.5 million, marking a year-over-year decrease of 4973.06%. This contributed to the annual value of $423.8 million for FY2024, which is 12336.49% up from last year.
- Per Summit Therapeutics' latest filing, its Current Assets stood at $246.5 million for Q3 2025, which was down 4973.06% from $309.2 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Current Assets high stood at $656.7 million for Q4 2022, and its period low was $79.4 million during Q2 2022.
- Its 5-year average for Current Assets is $243.2 million, with a median of $205.0 million in 2023.
- Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 57485.2% in 2022, then plummeted by 7111.18% in 2023.
- Summit Therapeutics' Current Assets (Quarter) stood at $97.3 million in 2021, then skyrocketed by 574.85% to $656.7 million in 2022, then crashed by 71.11% to $189.7 million in 2023, then skyrocketed by 123.36% to $423.8 million in 2024, then tumbled by 41.84% to $246.5 million in 2025.
- Its Current Assets stands at $246.5 million for Q3 2025, versus $309.2 million for Q2 2025 and $370.8 million for Q1 2025.